JP2010539082A5 - - Google Patents

Download PDF

Info

Publication number
JP2010539082A5
JP2010539082A5 JP2010524063A JP2010524063A JP2010539082A5 JP 2010539082 A5 JP2010539082 A5 JP 2010539082A5 JP 2010524063 A JP2010524063 A JP 2010524063A JP 2010524063 A JP2010524063 A JP 2010524063A JP 2010539082 A5 JP2010539082 A5 JP 2010539082A5
Authority
JP
Japan
Prior art keywords
salt
complex according
cyclodextrin
complex
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010524063A
Other languages
English (en)
Japanese (ja)
Other versions
JP5474792B2 (ja
JP2010539082A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/056393 external-priority patent/WO2009035718A1/en
Publication of JP2010539082A publication Critical patent/JP2010539082A/ja
Publication of JP2010539082A5 publication Critical patent/JP2010539082A5/ja
Application granted granted Critical
Publication of JP5474792B2 publication Critical patent/JP5474792B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010524063A 2007-09-10 2008-03-10 亜鉛結合部分を含むキナゾリンベースｅｇｆｒインヒビターの酒石酸塩またはその複合体 Expired - Fee Related JP5474792B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97105607P 2007-09-10 2007-09-10
US60/971,056 2007-09-10
PCT/US2008/056393 WO2009035718A1 (en) 2007-09-10 2008-03-10 Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety

Publications (3)

Publication Number Publication Date
JP2010539082A JP2010539082A (ja) 2010-12-16
JP2010539082A5 true JP2010539082A5 (enExample) 2011-03-24
JP5474792B2 JP5474792B2 (ja) 2014-04-16

Family

ID=40452375

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010524063A Expired - Fee Related JP5474792B2 (ja) 2007-09-10 2008-03-10 亜鉛結合部分を含むキナゾリンベースｅｇｆｒインヒビターの酒石酸塩またはその複合体

Country Status (7)

Country Link
US (3) US7846938B2 (enExample)
EP (1) EP2190287B1 (enExample)
JP (1) JP5474792B2 (enExample)
AU (1) AU2008299896B2 (enExample)
CA (1) CA2698944C (enExample)
ES (1) ES2526718T3 (enExample)
WO (1) WO2009035718A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2662617C (en) 2006-09-11 2014-11-18 Changgeng Qian Quinazoline based egfr inhibitors containing a zinc binding moiety
CN101570516B (zh) * 2009-04-14 2011-01-05 重庆威尔德·浩瑞医药化工有限公司 一种制备4-(3-氯-4-氟苯基胺基)-7-甲氧基-6-[3-(4-吗啉基)丙氧基]喹唑啉的方法
CN102452988B (zh) * 2010-10-27 2016-01-27 中国科学院化学研究所 一种喹唑啉衍生物及其制备方法
CN103648500B (zh) 2011-03-17 2016-05-04 宾夕法尼亚大学理事会 双功能酶制钳型分子的方法和用途
US9295676B2 (en) 2011-03-17 2016-03-29 The Trustees Of The University Of Pennsylvania Mutation mimicking compounds that bind to the kinase domain of EGFR
US20140229256A1 (en) 2013-02-11 2014-08-14 Solutran Product substantiation using approved product list system and method
CN102276500A (zh) * 2011-05-05 2011-12-14 西安交通大学 水杨酰胺类抗肿瘤化合物及其合成方法和用途
WO2013062344A1 (en) * 2011-10-28 2013-05-02 Chong Kun Dang Pharmaceutical Corp. Hydroxamate derivatives for hdac inhibitor, and the pharmaceutical composition comprising thereof
WO2013159698A1 (zh) * 2012-04-26 2013-10-31 深圳信立泰药业股份有限公司 稠环喹唑啉羟肟酸类化合物及其作为抗肿瘤药物的应用
CN102898315B (zh) * 2012-11-05 2015-01-28 上海毕得医药科技有限公司 3-乙炔基-4-氟苯胺的制备方法
US10552861B2 (en) 2013-02-11 2020-02-04 Solutran, Inc. Dual redemption path with shared benefits system and method
KR20170040798A (ko) * 2014-08-08 2017-04-13 포사이트 비젼4, 인크. 수용체 티로신 키나제 억제제의 안정한 가용성 제제 및 그의 제조 방법
CN105693630B (zh) * 2016-03-10 2018-02-16 田静 一种吉非替尼中间体的制备方法
US12630501B2 (en) 2019-09-08 2026-05-19 Hadasit Medical Research Services And Development Ltd. Anti-fibrotic compounds and use thereof
US12100049B2 (en) 2020-06-05 2024-09-24 Soltran, LLC Filtered POS processing of services
CN116710448B (zh) * 2021-01-20 2025-05-16 莱托克斯有限公司 被保护的hdac(组蛋白脱乙酰酶)抑制剂
US12530346B2 (en) 2021-12-24 2026-01-20 Solutran, LLC Data transmission filtering through a customized filter list

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
CA2124306C (en) * 1993-05-26 2004-04-06 Masami Muraoka Quinazolinone derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508537D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US7572798B2 (en) 2001-02-26 2009-08-11 Mcgill University Combi-molecules having signal transduction inhibitory properties and DNA damaging properties
AU2003257666A1 (en) 2002-08-23 2004-03-11 Kirin Beer Kabushiki Kaisha COMPOUND HAVING TGFss INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2006515871A (ja) * 2003-01-23 2006-06-08 ティー．ケイ． シグナル リミテッド 上皮増殖因子受容体チロシンキナーゼの不可逆阻害剤ならびにその使用
PE20040945A1 (es) * 2003-02-05 2004-12-14 Warner Lambert Co Preparacion de quinazolinas substituidas
MXPA06003341A (es) * 2003-09-25 2006-06-08 Astrazeneca Ab Derivados de quinazolina.
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
WO2005097137A2 (en) 2004-03-31 2005-10-20 The Scripps Research Institute Advanced quinazoline based protein kinase inhibitors
NZ589276A (en) 2005-02-03 2012-06-29 Topotarget Uk Ltd Combination therapies using hdac inhibitors and erlotinib (tarceva)
JP2008535924A (ja) * 2005-04-12 2008-09-04 エラン ファーマ インターナショナル リミテッド ナノ粒子キナゾリン誘導体製剤
US20070027150A1 (en) 2005-04-14 2007-02-01 Bellamacina Cornelia R 2-Amino-quinazolin-5-ones
ITMI20050729A1 (it) * 2005-04-22 2006-10-23 Endura Spa Nuova formulazione biologicamente attiva
EP2018366A4 (en) 2006-05-16 2010-08-04 Univ Mcgill HYBRID MOLECULES WITH MIXED VITAMIN D RECEPTOR AGONISM AND HISTONDEACETYLASE RESISTANT PROPERTIES
AU2007296745B2 (en) 2006-09-11 2011-12-01 Curis, Inc. Quinazoline based EGFR inhibitors
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
CA2662617C (en) * 2006-09-11 2014-11-18 Changgeng Qian Quinazoline based egfr inhibitors containing a zinc binding moiety
SG174772A1 (en) 2006-09-11 2011-10-28 Curis Inc Multi-functional small molecules as anti-proliferative agents
CA2667826C (en) 2006-10-28 2013-10-08 Methylgene Inc. Inhibitors of histone deacetylase
US8119616B2 (en) 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety

Similar Documents

Publication Publication Date Title
JP2020511467A5 (enExample)
JP2011511073A5 (enExample)
TWI594986B (zh) Antineoplastic agent effect enhancer
JP2012505916A5 (enExample)
JP2010523476A5 (enExample)
JP2009533482A5 (enExample)
JP2017509586A5 (enExample)
JP2013537203A5 (enExample)
JP2012506381A5 (enExample)
JP2014512356A5 (enExample)
JP2005500300A5 (enExample)
JP2013189456A5 (enExample)
JP2010526814A5 (enExample)
JP2006503919A5 (enExample)
JP2015508103A5 (enExample)
JP2017530171A5 (enExample)
JP2012526766A5 (enExample)
JP2012180344A5 (enExample)
JP2014518544A5 (enExample)
JP2015512943A5 (enExample)
HRP20160545T1 (hr) Inhibitor fosfoinozitid 3-kinaze sa dijelom koji veže cink
JP2017524013A5 (enExample)
RU2019110876A (ru) Композиции, содержащие источник металла, дитиокарбамат и циклодекстрин
JP2010528122A5 (enExample)
JP2010530002A5 (enExample)